Pancreatic Cancer Research

ResearcherSeoul National UniversityActive in the last 2 years

Jae Woo Lee

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-0735-5707; OpenAlex author ID A5020724911; NIH RePORTER profile ID 11077258. Sources: OpenAlex.

Their work

Papers
14 (first author 2, last author 0)
Trials
0
Grants
1
Labs led
0
Collaborators
69
Papers, trials and grants by year

2016: 1 paper, 1 grant · 2017: 3 papers · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: 2 papers · 2024: 2 papers · 2025: none · 2026: 6 papers

Papers 14

  1. Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial. Co-author DOI 10.1038/s41467-026-68324-4↗
  2. Publisher Correction: Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial Co-author DOI 10.1038/s41467-026-71968-x↗
  3. Cancer-Associated Fibroblasts Promote Epithelial-Mesenchymal Transition and Classical to Basal Subtype Shift in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-25-0331↗
  4. A Randomized Phase II Study: CRS207/GVAX plus Anti-PD-1 and Anti-CTLA4 Recruits Mesothelin- and mKRAS-Specific T Cells into PDAC. Co-author DOI 10.1158/2326-6066.cir-25-0545↗
  5. Computational Modeling of Cellular Influence Delineates Functionally Relevant and Distinct Cellular Neighborhoods in Primary and Metastatic Pancreatic Ductal A… First author DOI 10.1158/2326-6066.cir-25-0844↗
  6. Cytometric Atlas of Combination Immunotherapy in Pancreatic Cancer: Blood-Based Signatures Reveal Vaccine and Checkpoint Inhibitor Responses. Co-author DOI 10.1158/2326-6066.cir-25-1126↗
  7. Multimodal immune phenotyping reveals microbial-T cell interactions that shape pancreatic cancer. Co-author DOI 10.1016/j.xcrm.2024.101397↗
  8. Transfer Learning Reveals Cancer-Associated Fibroblasts Are Associated with Epithelial-Mesenchymal Transition and Inflammation in Cancer Cells in Pancreatic Du… Co-author DOI 10.1158/0008-5472.can-23-1660↗
  9. Screening for pancreatic cancer has the potential to save lives, but is it practical? First author DOI 10.1080/17474124.2023.2217354↗
  10. Treatment Response in First-Line Metastatic Pancreatic Ductal Adenocarcinoma Is Stratified By a Composite Index of Tumor Proliferation and CD8 T-Cell Infiltrat… Co-author DOI 10.1158/1078-0432.ccr-23-0535↗
  11. Tumor-Derived CCL2 Mediates Resistance to Radiotherapy in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-16-0870↗
  12. IL6 Receptor Blockade Enhances Chemotherapy Efficacy in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1535-7163.mct-16-0899↗
  13. Efficacy of Capecitabine Plus Oxaliplatin Combination Chemotherapy for Advanced Pancreatic Cancer after Failure of First-Line Gemcitabine-Based Therapy. Co-author DOI 10.5009/gnl16307↗
  14. Genetically Engineered Mouse Models of Pancreatic Cancer: The KPC Model (LSL-Kras(G12D/+) ;LSL-Trp53(R172H/+) ;Pdx-1-Cre), Its Variants, and Their Application … Co-author DOI 10.1002/cpph.2↗

Grants 1

  1. A role for macrophage phenotype in regulating metastasis in pancreatic carcinoma F30CA196106↗

Closest collaborators

The 25 strongest of 69 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Won Jin Ho · 7 shared papers, 2024–2026 · strength 1.46
  2. Elizabeth M. Jaffee · 7 shared papers, 2024–2026 · strength 1.43
  3. Elana Judith Fertig · 6 shared papers, 2024–2026 · strength 1.15
  4. Hao Wang · 4 shared papers, 2026 · strength 0.83
  5. Katherine M. Bever · 4 shared papers, 2026 · strength 0.83
  6. Luciane Tsukamoto Kagohara · 4 shared papers, 2024–2026 · strength 0.70
  7. Robert A. Anders · 3 shared papers, 2026 · strength 0.61
  8. Janelle Marie Montagne · 3 shared papers, 2026 · strength 0.61
  9. Amanda L. Huff · 3 shared papers, 2026 · strength 0.61
  10. Nicole Groß · 3 shared papers, 2024–2026 · strength 0.57
  11. Jacob T. Mitchell · 3 shared papers, 2024–2026 · strength 0.56
  12. Gregory Lawrence Beatty · 5 shared papers, 2016–2024 · strength 0.55
  13. Yeonju Cho · 2 shared papers, 2026 · strength 0.47
  14. Dung Thi Le · 2 shared papers, 2026 · strength 0.45
  15. Laura DeLong Wood · 2 shared papers, 2024–2026 · strength 0.42
  16. Saurav Daniel Haldar · 2 shared papers, 2026 · strength 0.38
  17. Marina Baretti · 2 shared papers, 2026 · strength 0.38
  18. Thatcher Ross Heumann · 2 shared papers, 2026 · strength 0.38
  19. Mark M. Yarchoan · 2 shared papers, 2026 · strength 0.38
  20. Neeha Zaidi · 2 shared papers, 2026 · strength 0.38
  21. Nilofer Saba Azad · 2 shared papers, 2026 · strength 0.38
  22. Daniel A. Laheru · 2 shared papers, 2026 · strength 0.38
  23. Michael Goggins · 2 shared papers, 2023–2026 · strength 0.36
  24. Dimitrios N. Sidiropoulos · 2 shared papers, 2024–2026 · strength 0.36
  25. Jin Peng He · 2 shared papers, 2024–2026 · strength 0.33

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.